Silverback Therapeutics, Inc., a biopharmaceutical company developing a pipeline of systemically delivered, locally active therapies, today announced Peter Thompson, M.D., co-founder, president and chief executive officer, will present corporate updates at the SVB Leerink Global Healthcare Conference on Tuesday, February 25, 2020, at 1:45 pm ET at the Lotte New York Palace Hotel.
A live audio webcast will be accessible on the company’s website and a replay of the webcast will be archived on the company’s website for 90 days.
About Silverback’s Platform ImmunoTAC™ Technology
Silverback’s proprietary technology and integrated R&D approach enables the design and development of ImmunoTAC™ therapeutics that can be administered systemically but act only at the sites of disease. Silverback’s platform technology facilitates the development of potent and targeted systemic therapies capable of locally modulating fundamental pathways underlying serious diseases with unmet need. This platform offers opportunities to address settings where traditional antibody and small molecule-based approaches have been unsuccessful due to lack of activity and/or unacceptable toxicities. Silverback has 4 issued U.S. patents and over 20 patent families directed to the platform and related product candidates.
About SBT6050; Silverback’s Lead ImmunoTAC™ Candidate
Silverback’s lead candidate, SBT6050, is a conjugate comprised of a potent, proprietary TLR8 agonist linked to a HER2-directed monoclonal antibody. Curative single agent activity has been shown in preclinical studies across both syngeneic models as well models lacking an adaptive immune system – a differentiated profile which the Company expects may translate into robust clinical efficacy. SBT6050 is on track to enter the clinic in 2020 for patients with moderate to high HER2-expressing solid tumors.
About Silverback Therapeutics
Silverback Therapeutics is a privately held biopharmaceutical company advancing a pipeline of first-in-class ImmunoTAC™ therapies that are systemically delivered but locally active and target fundamental disease pathways. Enabled by the company’s proprietary platform, Silverback’s pipeline is rapidly advancing towards clinical studies in several therapeutic areas, including oncology and fibrosis. Since its inception in 2016, Silverback has raised $65 million in venture capital financing from OrbiMed, Bristol-Myers Squibb, and Alexandria Venture Investments. The company is headquartered in Seattle, Washington. For more information, please visit www.silverbacktx.com.